drugset / Trial / NCT01485874
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
Timeline
- Start
- 2011-11
- Primary completion
- 2015-12
- Completion
- 2015-12
Publications
- Background Maria Creselda deLeon, Alesha Arnold, Emma Caroline Rossi, Jamie Case, Cynthia Johnson, Yan Zeng, Daniela Matei. Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149. J Clin Oncol 32:5s, 2014 (suppl; abstr 5541^)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 100 mg | Oral |
| Subject | Nintedanib | Small molecule | 150 mg | Oral |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |
| Background | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |